Literature DB >> 8500223

Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.

Y Zou1, W Priebe, Y H Ling, R Perez-Soler.   

Abstract

Annamycin (Ann) is a lipophilic, non-cross resistant anthracycline antibiotic that is easily amenable to formulation in a wide variety of liposomal carriers. We studied the organ distribution and tumor uptake of Ann entrapped in multilamellar vesicles (L-Ann), free annamycin (F-Ann), and doxorubicin (DOX) in C57BL/6 mice bearing advanced subcutaneous B16 melanoma tumors. L-Ann was composed of DMPC: DMPG: Ann at a molar ratio of 7:3:0.7. Mean particle size was 1.88 +/- 0.89 microns, and the entrapment efficiency was 93.08% +/- 2.96%. F-Ann was prepared as a suspension (particle size < or = 0.2 microns) in 10% DMSO. Drug levels were measured by fluorescence spectrometry after extraction with chloroform. The extraction ratio ranged between 60% and 90% for both drugs in most tissues. Compared with those of DOX, organ AUCs of L-Ann were threefold higher in plasma and brain, twofold higher in liver and kidney, sixfold higher in lung, ninefold higher in spleen, and tenfold higher in B16 tumors. Compared with F-Ann, organ AUCs of L-Ann were twofold higher in plasma, liver, and B16 tumors and were twofold lower in brain. Heart AUCs were similar with all three drugs. Higher tumor uptake was associated with a faster penetration and more prolonged retention of Ann in tumor tissue compared with those of DOX. The results obtained indicate significant differences in organ distribution between L-Ann and DOX as a result of the higher affinity of Ann for lipid membranes and the use of the liposomes as a delivery system. The potential clinical relevance of the increased uptake of L-Ann in B16 tumors, lung, and brain is being investigated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500223     DOI: 10.1007/BF00685834

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.

Authors:  S Oudard; A Thierry; T J Jorgensen; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

Authors:  A Gabizon; A Dagan; D Goren; Y Barenholz; Z Fuks
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

3.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.

Authors:  A Gabizon; D C Price; J Huberty; R S Bresalier; D Papahadjopoulos
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

4.  3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.

Authors:  N Horichi; H Tapiero; Y Sugimoto; M Bungo; M Nishiyama; A Fourcade; T J Lampidis; K Kasahara; Y Sasaki; T Takahashi
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

5.  Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).

Authors:  J Lautersztain; R Perez-Soler; A R Khokhar; R A Newman; G Lopez-Berestein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.

Authors:  L Lothstein; T W Sweatman; M E Dockter; M Israel
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

7.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

8.  Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.

Authors:  J A Balazsovits; L D Mayer; M B Bally; P R Cullis; M McDonell; R S Ginsberg; R E Falk
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery.

Authors:  A R Khokhar; K Wright; Z H Siddik; R Perez-Soler
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; G White; N More; P S Schein
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  4 in total

1.  Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors:  K M Wasan; R E Morton
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.

Authors:  R Perez-Soler; Y H Ling; Y Zou; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

4.  Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences.

Authors:  D Wagner; W V Kern; P Kern
Journal:  Clin Investig       Date:  1994-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.